San Diego-primarily based Viking Therapeutics marked by itself as a serious competitor within the weight loss drug current market in February soon after revealing promising facts from a mid-stage trial of experimental drug VK2735, which prompt it rivaled—and outperformed—Novo and Lilly drugs when given as being a weekly injection As well as in